Crocs, Inc. vs InMode Ltd — how do they compare? Crocs, Inc. trades at $116.68 (market cap $5.53B), while InMode Ltd trades at $14.07 (market cap $806.05M). The key difference: Crocs, Inc. is far larger — about 6.9× InMode Ltd's market cap, and Crocs, Inc. is trading nearer its 52-week high, InMode Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crocs, Inc. for 96 Days and InMode Ltd for 29 Days on average.
| CROX | INMD | |
|---|---|---|
Market Cap | $5.53B | $806.05M |
Volume | 967,176 | 511,446 |
Sector | Consumer Cyclical | Health |
52-Week High | $141.19 | $16.62 |
52-Week Low | $73.39 | $12.76 |
Typical Hold Time | 96 Days | 29 Days |
Enterprise Value | $7.04B | $309.39M |
Signals from Pluang's Aura AI — not financial advice
Crocs (CROX) trades at $116.84, down 2.81% today, amid bearish technical signals but strong fundamental valuation metrics. The stock shows attractive P/E of 10.23 and P/S of 1.46, with robust profitability margins including 57.47% gross margin and 42.3% ROE. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $4.55 surpassing the $4.35 estimate. The company maintains strong cash flow generation despite a net loss in 2025, with management focusing on product innovation and HEYDUDE brand repositioning.
CROX presents a compelling value opportunity with discounted valuation multiples relative to historical performance, though near-term technical weakness and competitive pressures warrant caution. Analyst consensus remains bullish with $136.78 price target representing 17% upside potential. Key risks include consumer discretionary spending sensitivity and execution challenges with brand diversification initiatives. The stock's current levels offer entry points for long-term investors seeking exposure to a profitable footwear company with strong brand recognition.
INMD trades at $14.01, showing minimal daily movement with a 0.14% gain. The stock faces bearish technical signals despite attractive valuation metrics including a P/E of 11.58 and EV/EBITDA of 4.43. Recent earnings show mixed results with Q2 2026 beating expectations but Q1 2026 missing, while the company faces shareholder activism from Steel Partners' $16.75 per share acquisition offer. Revenue guidance for 2026 remains stable at $365M-$375M.
The investment case balances strong profitability margins against technical weakness and activist pressure. With 45% analyst buy ratings and no sell recommendations, fundamental value appears intact, but near-term price action suggests caution. Key catalysts include Q3 2026 earnings and resolution of the acquisition proposal, while risks include execution challenges and macroeconomic headwinds affecting aesthetic medicine demand.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company include Americas, Asia pacific, and EMEA.
Read more on CROX →InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →